ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
European Institute of Oncology (IEO) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
European Institute of Oncology (IEO) takes part in 27 sessions at ESMO 2026 in Madrid. Its program spans cancer treatment and precision oncology, with particular attention to lung and ovarian cancers. Topics include treatment selection for ovarian cancer and targeted approaches for lung cancer with actionable genetic changes.
| Organization | ESMO 2026 Attendance |
|---|---|
European Institute of Oncology (IEO) Milan, Italy | |
Private cancer hospital and research institute in Milan, Italy, recognised by the Italian state as a research hospital. | Satellite Fri Oct 23 09:45–11:15 Satellite Fri Oct 23 09:45–11:15 MSD - Emerging Evidence and Treatment Integration in Ovarian and Endometrial Cancer Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 09:45–09:48 Welcome Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 09:58–10:18 Major Data Highlights and Clinical Implications for PROC Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 10:10–10:30 Tackling NSCLC Harboring Actionable Genomic Alterations Lung & thoracic cancers Satellite Fri Oct 23 10:23–10:38 Case‑based discussion on treatment selection and sequencing in ovarian cancer Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 10:50–11:10 Keeping the Patient in the Center Lung & thoracic cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Health-related quality of life (HRQoL) among patients with advanced or metastatic RET-fusion-positive NSCLC treated with pralsetinib in ARROW Lung & thoracic cancersNursing & supportive care Poster Fri Oct 23 13:00–15:00 Molecular Tumor Boards in patients with sarcoma: A real-world experience Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Virtual reality and body perception: A pilot study with breast cancer survivors Breast cancerNursing & supportive care Chair Fri Oct 23 13:30–15:00 Update on the mangement of endometrial cancer in the era of molecular classification Gynaecological cancers Poster Fri Oct 23 15:15–16:00 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HR+, HER2-low metastatic breast cancer: A DESTINY-Breast06 ctDNA molecular response analysis Breast cancerBiomarkers & precision oncology Chair Fri Oct 23 16:15–17:45 Rapid oral 1: Gynaecological cancers Gynaecological cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Abstract Sat Oct 24 15:57–16:07 Invited Discussant LBA38 and 1240O Gynaecological cancers Chair Sat Oct 24 16:30–17:45 A multidisciplinary approach to Mixed Neuroendocrine-Non- neuroendocrine Neoplasms (MiNEN) Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 16:30–16:35 Presentation of case/condition Sarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:55–19:15 Expanding the Reach – Novel Combinations and Non-Biomarker Selected Therapies Gynaecological cancers Satellite Sat Oct 24 19:35–19:50 Future Directions and Case-Based Application Gynaecological cancers Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 MIRAGE and FlowPath: An open-source framework for end-to-end multiplexed immunofluorescence analysis and spatial cell phenotyping Sarcoma, CNS, head & neck and rare cancers Poster Sun Oct 25 12:00–12:45 Role of liquid biopsy guided molecular hyperselection for anti-EGFR therapy in refractory metastatic colorectal cancer (mCRC): A pooled analysis of four trials Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 SyntheX: Biologically constrained synthetic transcriptomic augmentation for prognostic modeling in small clinical cohorts Haematological malignanciesMelanoma & skin cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers Satellite Sun Oct 25 13:27–13:52 Shaping long-term outcomes in first-line treatment for EGFR-mutant NSCLC Lung & thoracic cancers Chair Sun Oct 25 16:30–18:15 Presidential Symposium II Lung & thoracic cancersGastrointestinal cancers Talk Mon Oct 26 08:30–08:55 Optimising therapy for locally advanced prostate cancer Genitourinary cancers Chair Mon Oct 26 08:30–10:00 Proffered paper 2: NSCLC, metastatic Lung & thoracic cancers Poster Mon Oct 26 12:00–12:45 Satellite Mon Oct 26 18:45–19:15 Satellite Mon Oct 26 19:15–19:25 Satellite Mon Oct 26 19:25–19:40 Talk Tue Oct 27 09:20–09:40 Talk Tue Oct 27 11:40–12:20 |
Find decision makers at European Institute of Oncology (IEO)
Tell us what you sell and we’ll find the people at European Institute of Oncology (IEO) most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction